Remove Events Remove Inpatient Remove Labelling
article thumbnail

Episode 918: What Happens If You Give a Cephalosporin to a Patient With Moderate, Severe, or Unknown Beta-Lactam Allergy?

Pharmacy Joe

Subscribe on iTunes , Android , or Stitcher The label of “penicillin allergic” usually sticks to a patient’s medical record forever. A 50 y/o male with an SSTI had an unknown allergy to penicillin, received a single dose of ceftriaxone in the ED and was then switched to piperacillin-tazobactam as an inpatient.

article thumbnail

Episode 547: How to predict the pharmacotherapy needs of your patient and team during an inpatient medical emergency

Pharmacy Joe

In this episode, I’ll discuss how to predict the pharmacotherapy needs of your patient and team during an inpatient medical emergency. This is when you do regular pharmacist things like drawing up and labeling medications, and calculating doses. This work is valuable because it frees a nurse up to be hands-on with a patient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 561: Rivaroxaban, mitral valves, and atrial fibrillation

Pharmacy Joe

To improve the data available in this patient population, investigators in Brazil completed a multicenter, randomized, open-label, noninferiority trial with 1000 patients comparing rivaroxaban with warfarin for patients with atrial fibrillation and a bioprosthetic mitral valve.

article thumbnail

Episode 863: Does This Randomized Trial Settle the Increased AKI from Piperacillin-Tazobactam Question?

Pharmacy Joe

The ACORN randomized trial sought to compare rates of AKI and neurotoxicity in patients hospitalized with acute infection who were randomized 1:1 in an open-label fashion to receive either piperacillin-tazobactam or cefepime for gram-negative coverage. However, other studies have examined a link between increased neurotoxicity with cefepime.

article thumbnail

Episode 863: Does This Randomized Trial Settle the Increased AKI from Piperacillin-Tazobactam Question?

Pharmacy Joe

The ACORN randomized trial sought to compare rates of AKI and neurotoxicity in patients hospitalized with acute infection who were randomized 1:1 in an open-label fashion to receive either piperacillin-tazobactam or cefepime for gram-negative coverage. However, other studies have examined a link between increased neurotoxicity with cefepime.

article thumbnail

Episode 741: Is it safe to use early antibiotic discontinuation in hematology patients with fever of unknown origin during chemotherapy-induced neutropenia?

Pharmacy Joe

Recently published in Lancet was a non-inferiority, open-label, multicentre, randomized trial that sought to clarify the safety of early antibiotic discontinuation in hematology patients with fever of unknown origin during chemotherapy-induced neutropenia.

article thumbnail

Episode 649: Do albumin infusions improve outcomes in hospitalized patients with decompensated cirrhosis?

Pharmacy Joe

A group of authors recently published in NEJM the results of a randomized, multicenter, open-label, parallel-group trial in the UK examining this issue. The authors also applied a time-to-event analysis in which data were censored at the time of discharge or at day 15. The most common cause for cirrhosis was alcohol.